Orogen Royalties Inc
XTSX:OGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Orogen Royalties Inc
XTSX:OGN
|
CA |
|
A
|
Aravali Securities and Finance Ltd
BSE:512344
|
IN |
|
Alignvest Acquisition II Corp
TSX:SFC
|
CA |
|
Evil Empire Designs Inc
OTC:EVVL
|
US |
|
Dollar Industries Ltd
NSE:DOLLAR
|
IN |
|
C
|
Chememan PCL
SET:CMAN
|
TH |
|
Eastone Century Technology Co Ltd
SZSE:300310
|
CN |
|
R
|
Rapid Dose Therapeutics Corp
CNSX:DOSE
|
CA |
|
Diebold Nixdorf Inc
NYSE:DBD
|
US |
|
Ascelia Pharma AB
STO:ACE
|
SE |
|
S
|
SD Standard ETC PLC
OSE:SDSD
|
CY |
|
Nepi Rockcastle NV
AEX:NRP
|
NL |
|
Keboda Technology Co Ltd
SSE:603786
|
CN |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is OGN's stock price target?
Not Available
OGN does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Orogen Royalties Inc?
Projected CAGR
-35%
Over the last 9 years, the compound annual growth rate for Revenue has been 60%. The projected CAGR for the next 1 year is -35%.
What is the Operating Income forecast for Orogen Royalties Inc?
Projected CAGR
-78%
The compound annual growth rate for Operating Income over the next 1 year is -78%.
What is the Pre-Tax Income forecast for Orogen Royalties Inc?
Projected CAGR
-43%
The compound annual growth rate for Pre-Tax Income over the next 2 years is -43%.
What is the Net Income forecast for Orogen Royalties Inc?
Projected CAGR
-11%
The compound annual growth rate for Net Income over the next 2 years is -11%.